The RA Redefined video matrix aims to educate on the evolving understanding behind the pathophysiology of rheumatoid arthritis (RA), the role of autoantibodies and cytokines in the disease, and how T cells and B cells perpetuate RA.
I recently heard of a secondary school assignment wherein students were challenged to “bury” a word that was no longer useful or appropriate. Their exercise has now evolved into an unofficial RheumNow task force to retire diagnostic terms that have grown into misuse in rheumatology and medicine. How did we decide which words should perish? And by what criteria? Who has the final say?
As the healthcare landscape continues to change, “no show” rates will be an important factor for clinical practice. Implementing even one or two of the following proposed changes may help improve your no show rates.
By recognizing the limitations of memory and patient recall, I tend to focus historic elements that have high predictive value and avoid time consuming worm-holes in history-taking that have low predictive value. This leaves me with more time to listen to the patient.
The word “access” is thrown around a lot these days, particularly regarding health care and specifically, prescription medications. Access to medications essentially revolves around two things: availability and affordability. Immediately, pharmaceutical manufacturers come to mind, as they are responsible for production and setting the list price. However, ultimate availability and affordability of medications is shared with another entity. The final arbiter of access is the Pharmacy Benefit Manager. Their power resides in the fact that they control the formulary and determine the “preferred drugs” list. How does this relate to the uptake of biosimilars?
Dr. Olga Petryna at EULAR2018 Discusses Pregnancy Outcomes with Secukinumab